Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations

Atherosclerosis
E J SijbrandsA H Smelt

Abstract

In patients heterozygous for familial hypercholesterolemia, the low-density lipoprotein (LDL) cholesterol lowering effect of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors may depend on the nature of the mutation in the LDL receptor gene. To test this hypothesis, we compared the response to simvastatin, 20 mg daily for 9 weeks, between heterozygous carriers of functionally different classes of mutations, i.e. mRNA negative or mRNA positive mutations. Out of 116 consecutive, unrelated patients with familial hypercholesterolemia, 27 patients were selected for molecular analyses: 14 patients with mRNA negative and 13 with mRNA positive mutations. Before simvastatin treatment, patients with mRNA negative mutations had higher levels of LDL cholesterol, lower levels of high-density lipoprotein (HDL) cholesterol and significantly more often tendon xanthomas, compared to patients with mRNA positive mutations. Simvastatin reduced the mean fasting LDL cholesterol levels to a similar percentage in the mRNA negative and mRNA positive patients (37, 36%, respectively, 95% CI of difference--8 to 5%, P = 0.2). This effect was similar to the 37% decrease observed in our total series of patients with familial hypercholesterolem...Continue Reading

References

Jan 1, 1992·Human Mutation·H H HobbsJ L Goldstein
May 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·P V KoivistoK Kontula
Aug 15, 1991·Biochemical and Biophysical Research Communications·B TopR R Frants
Apr 1, 1990·The Journal of Clinical Investigation·E LeitersdorfH H Hobbs
Apr 30, 1988·British Medical Journal·D G Altman, M J Gardner
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P T MaM S Brown
Apr 4, 1986·Science·M S Brown, J L Goldstein
Oct 1, 1981·The Journal of Clinical Investigation·R F TrecartinA Cao
Feb 1, 1995·Current Opinion in Lipidology·C J Packard, J Shepherd
Nov 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·P V KoivistoK Kontula
Oct 1, 1993·Nature Genetics·M Grompe
Oct 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M J KotzeG A Coetzee

❮ Previous
Next ❯

Citations

Jul 17, 2001·Clinical Genetics·J U Brorholt-PetersenO Faergeman
Sep 18, 1998·Current Opinion in Lipidology·P NichollsC A Graham
Dec 17, 2004·Human Genomics·Jose M Ordovas
Oct 6, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·Despoina M Choumerianou, George V Z Dedoussis
Dec 31, 2010·Vascular Health and Risk Management·Mohammad Hassan Nemati, Behrooz Astaneh
Nov 8, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Athanasios VergopoulosHerbert Schuster
Mar 30, 2005·Expert Opinion on Drug Safety·Rodrigo AlonsoPedro Mata
Oct 3, 2015·Pharmacogenomics·Paulo Caleb Junior Lima Santos, Alexandre Costa Pereira
May 21, 2004·Expert Review of Cardiovascular Therapy·Alpo F VuorioHelena Gylling
Oct 30, 2015·Circulation·Samuel S GiddingUNKNOWN American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascula
May 23, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·F H O'NeillR P Naoumova
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Pedro MataJuan Badimón
Aug 3, 2019·Journal of Clinical Lipidology·Chiara PavanelloRosellina Margherita Mancina

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.